The agreement consists of a $100 million revolving credit facility, a $100 million initial term loan, and a $50 million delayed-draw term loan.
The company drew $49 from the credit facility to repay an earlier outstanding loan and expects to draw another $27 million to, in part, pay for its acquisition of GenePOC.
The firm expects to offer nearly 5 million shares and also noted that this week it entered into an amended credit facility.
NanoString will initially draw $60 million at close, which will net it approximately $8 million after repaying its existing debt with the investment firm.
The new agreement amends a deal reached in October to partially fund its acquisition of some Alere businesses. That agreement was for $270 million.
NeoGenomics has now redeemed 100 percent of the $110 million preferred stock issues in conjunction with the Clarient acquisition, at a cost of $105 million.
The company said it will use the proceeds for technology development and to expand its global footprint, among other things.
The company will use a portion of the credit facility to fund its announced acquisition of Integrated DNA Technologies.
The company entered an agreement with JP Morgan Chase that provides a five-year unsecured $300 million term loan and a $1.5 billion revolving facility.
The company immediately borrowed $255 million to pay part of the $680 million price tag for Alere's MeterPro cardiovascular and toxicology business and its BNP assay business.
A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.
A new analysis finds some cancers receive more nonprofit dollars than others.
An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.
In Science this week: comparative analysis of sex differences in mammal gene expression, and more.